3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
2
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Scleroderma, Localized
1
Radiation Injuries
1
Prostatic Neoplasms
1
Popliteal Cyst
1
Polycystic Ovary Syndrome
1
Pneumonia
1
Neurodermatitis
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Multiple Myeloma
1
Lymphoma, Large B-Cell, Diffuse
1
Lichen Planus
1
Leukemia, Hairy Cell
1
Leukemia
1
Keratoacanthoma
1
Keloid
1
Hemangioma
1
Head and Neck Neoplasms
1
Granuloma Annulare
1
Dermoid Cyst
1
Dendritic Cell Sarcoma, Interdigitating
1
Cicatrix, Hypertrophic
1
Carcinoma, Non-Small-Cell Lung
1
Cancer Pain
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Methotrexate
8
Adalimumab
7
Etanercept
5
tocilizumab
4
Rituximab
4
tofacitinib
3
Abatacept
3
olokizumab
2
golimumab
2
Tumor Necrosis Factor Inhibitors
2
Antirheumatic Agents
2
upadacitinib
1
secukinumab
1
sarilumab
1
mavrilimumab
1
baricitinib
1
andecaliximab
1
Vitamin D
1
Vaccines
1
TACI receptor-IgG Fc fragment fusion protein
1
Syringes
1
Sulfasalazine
1
Saline Solution
1
Leflunomide
1
Hydroxychloroquine
1
Herpes Zoster Vaccine
1
Folic Acid
1
Fish Oils
1
Fatty Acids, Omega-3
1
Eicosapentaenoic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Arthritis, Rheumatoid
×
Adrenal Cortex Hormones
×
Clear all
NCT02046603
2018-12-07
ACT-MOVE
Hoffmann-La Roche
Phase 3
Completed
162 enrolled
30 charts